- Our Doctors
- Dr David Cutter
/content/dam/genesiscare/headshots/uk-doctor-headshots/UK_oncology_headshot_david_cutter.png
Dr David Cutter
Dr David Cutter
David
Cutter
MBBChir, MRCP, FRCR, DPhil, Clinical oncologist
Languages spoken
English
Expert in
Blood cancer
Overview
Centers
Oxford
Oxford
Peters Way, Sandy Lane West, Oxford, Oxfordshire, OX4 6LB, England, UK
51.7239071200697, -1.2145938932540707
/uk/our-centres/oxford
Oxfordshire
Milton Keynes
Milton Keynes
Sunrise Parkway, Linford Wood, Milton Keynes, Buckinghamshire, MK14 6LS, England, UK
52.05838, -0.76101
/uk/our-centres/milton-keynes
Buckinghamshire
Specialises in
Blood cancer
Treatments
Dr David Cutter is a recognised Clinical Oncologist based in Oxford and specialises in radiotherapy for Haematological Malignancies. Dr Cutter studied at the University of Cambridge and trained in Oncology at the Oxford Cancer Centre. He is currently a Consultant Clinical Oncologist and Senior Clinical Research Fellow at the University of Oxford.
.svg){kind=icon}
Career Positions
Current position(s)
- Consultant Clinical Oncologist, Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Education
Universities
- University of Cambridge and trained in Oncology at the Oxford Cancer Centre
- Senior Clinical Research Fellow at the University of Oxford
Expertise and interests
Expertise
- Blood cancer
Interests
- Radiotherapy for haematological malignancies
Professional memberships
- Royal College of Radiologists
- Royal College of Physicians
- National Cancer Research Institute Lymphoma Research Group (and Hodgkin lymphoma sub-group)
- UK Lymphoma Radiotherapy Group (Steering Committee member)
Accomplishments
Awards
- Frank Doyle (‘Gold’) medal for Fellowship of the Royal College of Radiologists (FRCR) exam
- British Heart Foundation Centre for Research Excellence DPhil Fellowship
- CCLG Scholarship to attend ESO-SIOPE Masterclass
- Royal College of Radiologists Cyclotron Trust visiting fellowship
- Cancer Research UK Programme Grant ‘Benefits and Risks of Cancer Treatment’
Publications
- Follows GA, Barrington SF, Bhuller KS, Culligan DJ, Cutter DJ, Gallop-Evans E, Kassam S, Osborne W, Sadullah S, Townsend W, Uttenthal BJ, Collins GP. Guideline for the First Line Management of Classical Hodgkin Lymphoma, A British Society for Haematology Guideline. Br J Haematol 2022 Feb 22. Online ahead of print (doi: 10.1111/bjh.18083)
- Jones DA, Candio P, Shakir R, Ntentas G, Ramroth J, Gray AM, Cutter DJ. Informing Radiotherapy Decisions in Stage I/IIa Hodgkin Lymphoma: Modelling Life Expectancy Using Radiation Dosimetry. Blood Adv 2021 Dec 6. Online ahead of print (DOI: 10.1182/bloodadvances.2021006254)
- Ntentas G, Dedeckova K, Andrlik M, Aznar MC, Shakir R, Ramroth J, Begum R, Kubeš J, Darby SC, Mikhaeel NG, Cutter DJ. Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection. IJROBP 2021 Nov 9. Online ahead of print (DOI: 10.1016/j.ijrobp.2021.10.151)
- Cutter DJ, Ramroth J, Diez P, Buckle A, Ntentas G, Popova B, Clifton-Hadley L, Hoskin PJ, Darby SC, Radford J, Illidge T. Predicted Risks of Cardiovascular Disease following Chemotherapy and Radiotherapy in the UK NCRI ‘RAPID’ Trial of PET-directed Therapy for Early-Stage Hodgkin Lymphoma. JCO 2021 Nov 10;39(32):3591-3601
- Zhang XY, Collins GP, Cutter DJ, Eyre TA. Limited-stage diffuse large B-cell lymphoma: current management and challenges. Br J Haematol 2021 Aug;194(3):508-517.